Healthcare Equipment and Supplies
Company Overview of Dune Medical Devices Corporation
Dune Medical Devices Corporation develops a tissue characterization technology that enables surgeons and radiologists to detect cancer in real-time. It offers MarginProbe System, a technology that detects cancer by assessing the electromagnetic response of tissue, as well as delivers real-time assessment on excised tissue in breast cancer surgery. The company was founded in 2002 and is based in Caesarea, Israel. It also has offices in Boston and Framingham, Massachusetts; Israel; and Switzerland.
20 Alon Hatavor Street
Industrial Park South
Founded in 2002
Key Executives for Dune Medical Devices Corporation
Chief Executive Officer and Director
Chief Financial Officer and Senior Vice President
Vice President of Finance & Administration
Compensation as of Fiscal Year 2014.
Dune Medical Devices Corporation Key Developments
Dune Medical Devices Corporation' MarginProbe System Available in the United States
Mar 19 13
Dune Medical Devices Corporation announced the MarginProbe System, a breakthrough intra-operative tissue assessment device used during lumpectomy surgery to treat early-stage breast cancer, is now available to patients in the United States, with the installation of the first System at University of California, Irvine Medical Center. Dune Medical Devices will be rolling out the MarginProbe System to additional hospitals across the U.S. in the coming months. The MarginProbe System, which received premarket approval from the US Food and Drug Administration on December 27, 2012, significantly improves surgeons' ability to intra-operatively identify 'cancer on the margin' and significantly reduce pathologically positive margins following a patient's initial lumpectomy surgery.
Dune Medical Devices Corporation Announces Results from the Pivotal Clinical Trial for the Marginprobe System
Mar 7 13
Dune Medical Devices Corporation announced that results from the pivotal clinical trial for the MarginProbe System, Dune's breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, were presented at the 66th Annual Society of Surgical Oncology (SSO) Cancer Symposium. FDA approval of the MarginProbe System was based on a 664 patient prospective, multi-center, randomized, double arm study to evaluate the effectiveness of MarginProbe System in identifying cancerous tissue along the margins of removed breast tissue during initial lumpectomy procedures. The MarginProbe System, which uses electromagnetic "signatures" to identify healthy and cancerous tissue, was found to be over three times more effective in finding cancer on the margin during lumpectomy, compared to traditional intra-operative imaging and palpation assessment. This enabled surgeons to significantly reduce the number of patients with positive margins following initial surgery.
Dune Medical Devices Corporation Announces European Union Approval of the MarginProbe System Type 1.2
Feb 19 13
Dune Medical Devices Corporation announced that it has received CE approval for compliance with the European Union's medical directive for its next generation MarginProbe System console. The MarginProbe System Type 1.2 is a more compact and portable version of the MarginProbe System console which will allow users greater flexibility while locating the hardware component of the MarginProbe System in their operating theaters. In addition to its improved aesthetics and compact size, the improvements in overall design allow for streamlined manufacturing and overall lower manufacturing costs.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 26, 2014
Most Searched Private Companies
Sponsored Financial Commentaries